BCMA Knockout RPMI-8226/Luciferase Cell Line

Description

BCMA Knockout RPMI-8226/Luciferase Cell Line is a human multiple myeloma model generated from RPMI-8226 cells using CRISPR/Cas9-mediated knockout of BCMA (B-cell maturation antigen) combined with stable luciferase reporter integration. This dual-modified line maintains plasma cell morphology and characteristic markers (CD38, CD138), while enabling highly sensitive, non-invasive tumor tracking through bioluminescence imaging. It serves as a critical negative control for evaluating BCMA-targeted therapies such as CAR-T and antibody-drug conjugates, while supporting research into BCMA-independent signaling and resistance pathways. Suitable for in vitro assays and in vivo tumor modeling, this line provides a robust tool for preclinical drug screening and mechanism studies. All cells are cryopreserved at low passage (<P20) and rigorously tested free of HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.